We are going to take a deep look at BioScrip Inc. (NASDAQ:BIOS) to get a better view of the company and its prevailing status, as well as the prospect it may offer for investors. Today’s prime focus will be a fundamental assessment of the equity from top to bottom.
As such, let’s begin with the top line, i.e. revenue trends. Last quarter, the firm saw its overall revenue came at $217.81M. That represents a change in revenues, on a quarterly/yearly basis, of -0.09%. If it is translated that into sequential terms, the firm witnessed sales decline by -0.1% from quarter to quarter.
It?s important to track the top line data. There’s no better way to compute the end market’s reception of a firm’s products. But no one wins without bottom line performance, which is what is required to look at next.
BioScrip Inc. (NASDAQ:BIOS) is intriguing when segregated to its core data. The cost of selling goods in preceding quarter was $159.21M, resulting in a gross basic income of $58.6M. For shareholders, provided the total diluted due shares of 118.78M, this means earnings per share of $(0.18). Note, this assesses with a consensus analyst projection of $-0.06 in EPS for its next quarterly report.
Given that data, now is the time to turn to a thorough glance across analyst projections for the firm going forward.
At present, analysts have a consensus average recommendation of Buy. This is grounded on a total of 6. While we don’t recommend taking analyst calls as face value strategies for action in a portfolio, we do consider it is vital to note where consensus is on an equity to understand what basic assumptions are possibly already discounted into pricing of shares.
As far as price targets, market analysts have an average target of $2.75. In addition, for next year, estimates of a fiscal year forecast is -0.15 in total EPS. On a median price to earnings ratio, that outlook results in a valuation of $9,999 times earnings.
For BioScrip Inc. (NASDAQ:BIOS), the firm presently holds around $21.1M in cash. That cash is balanced against around $22.43M in total current liabilities.
The firm?s debt is $falling, while total assets are $602.42M balanced by total liablities of $575.88M. The free cash flow last quarter was $(12.72M), representing a net change in cash of $11.53M. On a net operating level, the cash flow was about $(11.03M).
Let’s take a look at the technical analysis.
The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is in highly overbought territory. Beware of a trend reversal.
We will apprise the interesting story of BioScrip Inc. (NASDAQ: BIOS) as new events transpire.